Close Menu

NEW YORK – Janssen presented data this week at the International Association for the Study of Lung Cancer's World Conference on Lung Cancer from the Phase I CHRYSALIS trial of its EGFR-MET bispecific antibody amivantamab in EGFR exon 20-mutated metastatic or unresectable non-small cell lung cancer. Among 81 patients previously treated with platinum-based chemotherapy, the overall response rate with amivantamab was 40 percent and the duration of response was 11.1 months. The median progression-free survival was 8.3 months and the median overall survival was 22.8 months.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.